Graham Cooper
Chairman bei KEZAR LIFE SCIENCES, INC.
Vermögen: - $ am 31.03.2024
Aktive Positionen von Graham Cooper
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KEZAR LIFE SCIENCES, INC. | Independent Dir/Board Member | 01.10.2017 | - |
Chairman | 12.05.2022 | - | |
Director/Board Member | 01.10.2017 | 12.05.2022 | |
BEAM THERAPEUTICS INC. | Director/Board Member | 10.10.2019 | - |
Independent Dir/Board Member | 10.10.2019 | - |
Karriereverlauf von Graham Cooper
Ehemalige bekannte Positionen von Graham Cooper
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
APPLIED MOLECULAR TRANSPORT INC. | Director/Board Member | 01.01.2020 | 27.01.2022 |
Chairman | 26.01.2022 | 08.03.2023 | |
Independent Dir/Board Member | 01.01.2020 | 08.03.2023 | |
UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 01.08.2017 | 25.05.2022 |
Independent Dir/Board Member | 01.08.2017 | 25.05.2022 | |
ASSEMBLY BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 08.03.2018 | 01.04.2019 |
Chief Operating Officer | 08.03.2018 | 01.04.2019 | |
Director of Finance/CFO | 08.03.2018 | 01.04.2019 | |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Director/Board Member | 10.09.2013 | 01.03.2016 |
Independent Dir/Board Member | 10.09.2013 | 01.03.2016 | |
RECEPTOS INC | Comptroller/Controller/Auditor | 01.12.2014 | 27.08.2015 |
Director of Finance/CFO | 14.02.2013 | 27.08.2015 | |
Investor Relations Contact | 14.02.2013 | 27.08.2015 | |
GERON CORPORATION | Director of Finance/CFO | 05.01.2012 | 07.12.2012 |
OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 01.05.2006 | 11.03.2011 |
Treasurer | 01.05.2006 | 11.03.2011 | |
░░░░░░░░ ░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░ ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Graham Cooper
University of California, Berkeley | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 15 |
Operativ
Director/Board Member | 6 |
Independent Dir/Board Member | 5 |
Director of Finance/CFO | 4 |
Sektoral
Health Technology | 10 |
Commercial Services | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
GERON CORPORATION | Health Technology |
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
KEZAR LIFE SCIENCES, INC. | Health Technology |
UNITY BIOTECHNOLOGY, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
BEAM THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Deutsche Bank Securities, Inc.
Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Finance |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Bioniz Therapeutics, Inc.
Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
- Börse
- Insiders
- Graham Cooper
- Erfahrung